Status:
TERMINATED
MRI of the Liver With Eovist
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better at diagnosing liver lesions.
Detailed Description
Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B ...
Eligibility Criteria
Inclusion
- known hepatocellular carcinoma
- undergoing MRI of the liver
Exclusion
- Contraindication to MRI with IV contrast
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01215838
Start Date
August 1 2010
End Date
January 1 2012
Last Update
October 14 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.